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1. Introduction
  The contest between malaria parasites and humans 
has continued since the evolution of mankind, with no 
resolution in sight[1]. With more than 200 million clinical 
cases and an estimated 700 000 deaths per annum, malaria 
is a major vector-borne disease that now rivals HIV/AIDS 
as the world most deadly infection[2,3]. Key contributors 
toward child death under age five were presented in Figure 
1. To date, five Plasmodium protozoa have been identified, 
including Plasmodium falciparum (P. falciparum ), 
Plasmodium vivax (P. vivax), Plasmodium ovale (P. ovale), 
Plasmodium malariae (P. malariae) and the recently 
discovered simian Plasmodium knowlesi (P. knowlesi), 
which infects human with malaria through transmission 
by the Anopheles mosquito[4-6]. Infections caused by P. 
falciparum and P. vivax have been reported extensively 
worldwide; until recently, P. knowlesi infection in humans 
occurred predominantly in Southeast Asia[7,8]. Infections 
caused by virulent P. falciparum and P. knowlesi are life 
threatening, as they might lead to fatal complications, while 
other species typically only cause milder symptoms[9].
  Interestingly, the relationship between the host genetic 
profile and susceptibility to malaria is intricately 
intertwined. Conferred genetic resistance to malaria is not 
only enhanced by modifications to the immune system 
such as the major histo-compatibility complex gene, but 
also certain inherited haemoglobin disorders or erythrocyte 
polymorphisms[11]. Variations in the haemoglobin HBB 
gene that give rise to the HbS allele are higher in malaria-
endemic areas where the heterozygous condition confers 
protection against severe malaria[12,13]. The Duffy-negative 
blood group resulting from the FY gene polymorphism is 
common in sub-Saharan Africa as it provides complete 
resistance to P. vivax infection, but it is not present in 
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Asia or South America[3]. The Fulani ethnic group in Mali 
has comparatively higher resistance to malaria than other 
neighbouring ethnic groups, primarily due to their distinct 
genetic background and high levels of anti-malarial 
antibodies[14,15]. However, the host’s genetic background is 
not the only key to determining susceptibility to malaria; 
the involvement of environmental factors, parasite genetic 
factors and multi-gene interactions also play pivotal roles[16]. 
As this review will described, we need to understand to 
a greater extent the complex parasite lifecycle, antigenic 
variation, human immunity and genetic resistance to malaria 
to maximally exploit new genetic control mechanisms for 
future implementation in malaria control programs. 
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Figure 1. Global causes of death among children under age five 
between year 2008 and 2011.
Source: Black et al 2010[10]; and World Health Statistics 2011[98]. 
 
2. Clinical symptoms
  Malaria infections may lead to various symptoms ranging 
from very mild to severe complications and even death. The 
majority of the clinical signs of this disease are caused by 
the asexual multiplication of the parasite in red blood cells 
(RBCs)[17]. The release of infective merozoites from RBCs 
along with numerous waste substances, such as haemozoin 
pigment, glycosyl-phosphatidyl-inositol and several 
parasite-derived molecules, stimulates pro-inflammatory 
cytokine production that eventually causes fever and other 
complications associated with malaria[18].
  The cyclic occurrence of malaria attack consists of cold 
and hot stages, during which host experiences a cold 
and shivering sensation, followed by fever, headache 
and convulsion, respectively. Added findings such as 
mild jaundice and an enlarged liver may be found in P. 
falciparum malaria. Anaemia is a common sign for all types 
of malaria[19]. Kakkilaya (2009) reported that the degree 
of malarial anaemia correlates with parasitaemia and 
schizontaemia. Pregnancy, secondary bacterial infections 
and bleeding disorders can also aggravate the anaemia. P. 
vivax and P. ovale have a strong preference for infecting 
only young RBCs, thereby limiting parasitaemia levels to 
approximately 1%-2%. P. malariae invades RBCs of all 
ages but at a much slower multiplication rate that results in 
limited parasitaemia and mild symptoms during infection, 
whereas P. falciparum and P. knowlesi invades RBCs of 
all ages and anaemia can therefore develop rapidly due to 
profound haemolysis[20,21]. 
 Complicated malaria on the contrary normally occurs in 
areas of low endemicity or in individuals with low immunity 
due to certain health risks. Cerebral malaria is one of the 
clinical manifestations of severe malaria which induced 
changes in mental status and coma[22]. Metabolic acidosis, 
on the other hand, is an important cause of deaths in 
severe malaria as it can lead to acute respiratory distress 
syndrome[23]. Miller et al (2002) pointed out that numerous 
factors have contributed to metabolic acidosis. Cytokine 
stimulation and decreased clearance by the liver plays a 
vital role in the elevation of lactic acid production.
3. Control and treatment
  The absolute capability for accurate malaria diagnosis 
before rational therapy deserves increasing attention in the 
face of rampant drug resistance. Correct and timely therapy 
of malaria is critical to delay the initiation of resistance and 
also to save cost on alternative drugs. Laboratory support 
and access to medical care are often out of reach in most 
malaria endemic areas of all affected countries. As a result, 
imprecise clinical diagnosis remains the exclusive basis 
of self-treatment for most of the febrile populations in 
malarious regions. Unfortunately, uncomplicated malaria 
symptoms mimic a large series of tropical diseases which 
impairs the diagnosis specificity, and this in turn encourages 
inappropriate use of anti-malarials and consequently 
increased the requirement of more expensive alternative 
drugs[24]. Although simple and inexpensive microscopy 
examination of Giemsa-stained thin or thick smears 
is regarded as the gold standard for malaria diagnosis, 
however, training and skills of microscopists, inadequate 
quality control and maintenance of laboratory equipments 
that lead to poor microscopy has greatly affected the 
sensitivity and specificity in routine diagnosis[2]. 
  In the past few decades, alternative laboratory methods 
have been developed and became available for detection of 
Plasmodium parasites in human patients including enzyme-
linked immunosorbent assay (ELISA), quantitative buffy 
coat centrifugal haematology system (QBC) and polymerase 
chain reaction (PCR)[2]. Generally, PCR is more repeatable 
and sensitive than standard microscopy especially in 
cases with low parasitemia levels or mixed infections. 
Accuracy of PCR varies with the selection of appropriate 
primers, collection and storage of samples as well as the 
extraction methods. Additionally, contaminations, high 
cost and complicated procedures hamper the regular use of 
these laboratory diagnosis methods[25-27]. Rapid diagnostic 
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test (RDT) on the other hand is a test strip or dipstick test 
that can be completed within 15 minutes with minimum 
training requirement. The principle of RDT relies on 
immunochromatography with monoclonal antibodies targeted 
against particular malarial antigens, histidine rich protein-2 
specific for P. falciparum (PfHRP-2) or parasite lactate 
dehydrogenase (pLDH). Today, most RDTs have achieved 
95% sensitivity for falciparum malaria.  Although easy to 
use and interpret, the high unit costs and low sensitivity 
of current RDTs to other Plasmodium infections in human 
will further determine the availability and implementation 
in resource-poor malarious areas[28,29]. Despite the obvious 
need for anti-malarial drug development or malaria vaccine 
development, a parallel commitment to advance diagnostic 
tools is also a pressing concern for malaria control. 
  Since the Plasmodium parasite was discovered as the cause 
of malaria in 1880, it has been a struggle to overcome and 
eradicate the disease. The parasite’s complex lifecycle and 
high metabolic adaptability, selection pressure and the high 
proliferation rate of Plasmodium in humans, as well as social 
issues in endemic area such as malnutrition, ignorance and 
poor diagnosis of the disease, have hindered any significant 
progress[30,31]. The comparisons between three control and 
treatment strategies of malaria are summarised in Table 1. 
  Malaria control has always relied on vector control and 
chemotherapy medications. Routine indoor residual 
spraying of insecticides was a principal strategy in the 
prevention of malaria transmission. Yet, insecticides, 
especially dichlorodiphenyl-trichloroethane (DDT), 
cause environmental problems and mosquitoes become 
increasingly resistant[36,37]. To solve such a predicament, 
insecticide-treated nets or long-lasting insecticide-treated 
nets (LLINS), to which pyrethroids of low toxicity have been 
applied, have been rapidly deployed over the past 10 years. 
The implementation of these vector control measures in 
malaria-stratified areas, especially in Southeast Asia and 
Africa, effectively reduced the prevalence and mortality rate 
by 25%[4,38]. The failure to replace the nets or the improper 
use of LLINs in their 3-year lifespan has led to a resurgence 
of malaria cases in most malarious areas. Moreover, the 
widespread use of pyrethroids and the continuing absence 
of new chemical insecticides pose increase risk towards 
the development of pyrethroid-resistance in anopheline 
mosquitoes[39,40]. Given the remarkable importance of vector 
control in combating malaria, preserving the susceptibility 
of mosquitoes to pyrethroids and other currently available 
insecticides is of critical significance[38]. 
  The promotion and emphasis of chemotherapy intervention, 
on the other hand, is to provide an efficacious treatment 
and cure. Highly effective and inexpensive chloroquine 
and sulfadoxine-pyrimethamine have been important anti-
malarial drugs in recent decades. However, the misuse 
and overuse of these anti-malarial drugs has caused the 
devastating emergence and spread of P. falciparum-
resistant strains from Asia to all areas with predominant P. 
falciparum infection[4,35,39]. Therefore, new anti-malarial 
interventions in the form of artemisinin combination 
therapies (ACTs) that have shown promising parasitologic 
clearance and excellent safety profiles were developed. 
ACTs combine naturally derived artemisinin, which is 
a fast-acting lactone endoperoxide, with a drug such as 
amodiaquine or lumefantrine to enhance its efficacy and 
longer-lasting therapeutic effects[39]. For replacement of 
existing ineffective anti-malarial drugs, ACTs are now the 
first-line treatment recommended by the World Health 
Organization. Despite their recent introduction, artemisinin 
therapies have actually been available and utilised as 
monotherapies in western Cambodia for more than 30 years. 
Extensive usage combined with the antigenic variation of the 
Plasmodium parasite had contributed to the development of 
artemisinin resistance in P. falciparum along the Cambodia-
Thailand border[35,40]. The emergence of such resistance 
poses a dangerous threat for global malaria control, as there 
is no alternative class of anti-malarial drugs available for 
substitution. This increases the possibility that artemisinin-
resistant strains of P. falciparum will soon strike the world 
and thwart the plan to globally eradicate malaria by 2015. 
Hence, novel concepts and rationally designed tools are 
Table 1 
Adoption of key malaria control strategies and its outcome.
Control strategies      Regions adopted  Outcome
Insecticide residual spraying (IRS) Africa, Americas, Europe, South-East 
Asia, Eastern Mediterranean andWestern 
Pacific[34] 
-  Mosquitoes killed and repelled[32]
-  Prevent seasonal increases in transmission[32]
-  Insecticide resistance developed[32-33]
-  Alleged safety and environmental hazards[34]
Insecticide treated nets (ITNs or 
LLINs) 
Africa, Americas, South-East Asia, Western 
Pacific and Eastern Mediterranen[34]
-  Regular usage reduced all-cause mortality rates in 
children[33,34]
-  Low toxicity to humans[38]
-  Rapid and durable effect[38]
-  Coverage and sustainability problems[34]
-  Emergence of pyrethroids resistance[33-,34, 38]
Chemotherapies with ACTs Africa, Americas, Eastern Mediterranean, 
South-East Asia and Western Pacific[34]
-  Treatment for chloroquine-resistant P. falciparum and P. 
vivax[34,35]
-  Improved treatment efficacy[35]
-  Oral artemisinin-based monotherapies increase risk of 
resistance development[34,35]
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urgently needed to strengthen the arsenal to combat malaria 
as well achieve eradication. 
4. Mechanisms of anti-malarial drug resistance
  Chloroquine is an anti-malarial drug that once saved 
millions of lives, but its resistance has also created massive 
challenges towards malaria control. Single, non-synonymous 
nucleotide substitutions at approximately 16 positions on 
the pfcrt transporter gene with one significant amino acid 
change in codon 76, Lys濚Thr (K76T), have been observed 
in chloroquine-resistant Plasmodium parasites[30,36]. The 
mutation in this gene that exhibits drug-resistant properties 
is accompanied by a set of at least three other changes in 
transmembrane domain 1, 4 and 9 to maintain the normal 
transporting function of CRT protein[30,41]. Meanwhile, 
polymorphisms in the energy-demanding glycoprotein pump 
pfmdr1 were reported as a major determinant in increasing 
Plasmodium resistance to quinoline- or methanol-based 
drugs such as mefloquine and lumefantrine, especially in 
malaria-endemic Asia countries[42,43]. 
  In countries where chloroquine-resistant malaria 
is prevalent, anti-folate drugs that interfere with the 
Plasmodium spp. folate pathway are commonly used as 
the first-line treatment. Both dihydrofolate reductase 
(DHFR) and dihydropteroate synthase (DHPS) are crucial 
catalysts for the conversion of dihydrofolate to fully reduced 
tetrahydrofolate, a co-factor essential in one-carbon 
transfer reactions in DNA, RNA and amino acid synthesis. 
Thus, the lethal effect of DHFR and DHPS inhibitors 
including pyrimethamine, cycloguanil and sulfonamides 
on Plasmodium spp. reaches its climax in the erythrocytic 
schizont stage during which DNA synthesis is arrested[44]. 
  Mutations in the dhfr- and dhps-coding genes have also 
been determined to contribute to anti-folate resistance. Point 
mutations in pfdhfr-ts at codons 108 (S108N), 51 (N51I) and 59 
(C59R) have been suggested to be allelic variants that confer 
significant pyrimethamine resistance[45,46]. Polymorphism 
I164L found in dhfr has also caused alarm in South America 
and East Africa recently. Ominously, the accumulation of all 
these mutations creates completely resistant mutants against 
anti-folate, intensifying the burden of selection pressure 
and the spread of resistance worldwide[47].
  Similar mutation patterns were found in the highly 
conserved dhps region that compromise sulfa drug efficacy. 
Codon changes at S436A/F, A437G, A581G and K540E are 
common in Southeast Asia and sub-Saharan Africa. A similar 
situation exists for the mechanisms of in vitro P. falciparum 
DHFR and DHPS inhibitor resistance; the presence of 
multiple mutations is directly proportional to the degree of 
drug resistance[48]. Since artemisinin, which comes from an 
ancient Chinese herb called qinghaosu (Artemisia annua), 
was discovered, considerable debate on the mechanisms of 
its action has occurred. Several studies have proposed that 
artemisinin might possess more than one mode of action by 
targeting haemozoin, parasite mitochondria or translationally 
controlled tumour protein, but none of these mechanisms 
have been convincingly proven to be of functional relevance 
to the anti-malarial activity of artemisinin[49-51]. PfATP6, 
a parasite-encoded sarco/endoplasmic reticulum Ca2+-
dependent ATPase has recently been proposed to be a 
key player in artemisinin activity[52]. With respect to the 
expression of PfATP6 in oocytes of African clawed frog 
(Xenopus laevis) that commonly studied as model organism, 
mutations in L263 residue near the PfATP6 binding site 
exhibit reduced susceptibility to artemisinins[51,53].
  Substantial progress has been made in uncovering the 
causative mechanisms of anti-malarial resistance; it is 
not surprising, however, that no conclusion can yet be 
drawn. Point mutation and copy number variations for 
several key genes have been established as the vital factors 
that affect drug binding and transport. The host defence 
mechanism and variability in drug metabolism will also 
influence therapy outcomes[54]. Ideally, a broad spectrum 
of epidemiologically tailored combination therapies will 
offer protection against anti-malarial resistance and may 
well contain the spread of resistant alleles between endemic 
regions or even across continents.
5. Current status of malaria vaccine development
  There is a general agreement that development of a safe, 
highly efficacious and affordable malaria vaccine would 
be a transformative tool that closes the gap left by other 
interventions[55]. Increased funding, greater awareness, and 
the discovery of Plasmodium parasite and Anopheles vector 
genome sequence have reinvigorated the development of new 
antigens and vaccine technologies. Considerable progress 
in the development of pre-erythrocytic and blood stage 
vaccines or even combination of multi-stage vaccines are on 
the move from laboratory to the real world. Depending on the 
forthcoming full trial results in 2014, RTS, S/AS01 vaccine 
is the first and only candidate vaccine that has managed to 
reach large-scale phase III clinical testing in seven African 
countries and WHO recommendation for licensing may be 
expected in 2015[56]. By targeting the pre-erythrocyte stage 
of the parasite, the sub-unit RTS, S vaccine is constituted of 
a fusion of recombinant circumsporozoite (CS) protein with 
antigen S of the hepatitis B virus formulated with a potent 
adjuvant. The protective efficacy and safety profile of RTS, 
S was reported to be consistent and promising by reducing 
the rate of all episodes of clinical malaria by 51% in Kenyan 
children aged 5-17 months[57]. 
  Stimulation of a strong antibody response is a strength of 
the RTS,S vaccine, but Th1 cellular immunity has always 
been the comparatively weaker component. Th1 responses 
are the primary defence against intra-cellular pathogens 
through induced production of nitric oxide by IFN-毭 and 
through cell-mediated cytotoxicity[58]. Underactive Th1 
capability and overactive Th2 activity characterize Th-
cell imbalance in vaccinated individual. With resulting 
failure to generate powerful Th1 response, individual is still 
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susceptible to the disease and the infected cells cannot be 
completely destroyed[59]. While RTS,S gives a better survival 
chance to the most vulnerable part of the population, it is 
clear that more has to be done in order to  raise the bar for 
high expectations of a malaria vaccine. In support of this 
view, heterologous prime-boost vaccination is a rational 
approach for improving efficacy induced by RTS, S/AS01 
alone[55,60,61]. Most recently, a pre-erythrocytic vaccine 
combination utilizing RTS,S/ AS01 and a non-replicative 
adenovirus serotype 35 vectored CS has been investigated 
extensively with interest to expand the possibility of 
developing a more efficacious second generation vaccines. 
This prime-boost regimen capitalizes on the priming role 
elicited by adenovirus 35 vector to enhance cell-mediated 
Th1 responses, followed by RTS,S booster that improve the 
magnitude and duration of both cellular and humoral arms 
of the immune system[60,62]. In preclinical trial the protective 
anti-CS immunoglobulin response remained potent with 
dramatically high levels of IFN-毭 CD8+ T cell responses[63,64]. 
Based upon these findings, a multicenter Phase 1/2a efficacy 
study has began in August 2011 to further examine this 
potential prime-boost combination in healthy malaria-naive 
humans[65]. Using the knowledge of DNA-based technology, 
an electroporation administered DNA vaccine EP1300 which 
contains polyepitopes with linker sequence of four various 
pre-erythrocytic antigens, CS, SSP2/TRAP (thrombospondin-
related adhesion protein), liver-stage antigen 1 (LSA-1) and 
exported protein 1 (Exp-1) has started their Phase 1a clinical 
assessment in the United States from 2010. Few further 
details are available but the immunogenicity and durability 
for prophylactic vaccination in humans deserve attention. 
The progress of this vaccine also touches on the important 
question of how to ensure the safety and tolerability of DNA-
based multiple epitopes approaches[66]. 
  Presently, clinical development of second class malaria 
vaccine through identification of blood stage antigens 
that induce antibodies with similar specificities to 
immunoglobulin preparation during naturally acquired 
immunity has gained momentum[67,68]. Analysis of sera from 
immune adults from endemic regions as well as those from 
passive transfer experiments contributes to the discovery 
of merozoite surface protein 3 (MSP3) and glutamate rich 
protein (GLURP) as potent antigens that induce anti-malarial 
immunity. GMZ2 is a recombinant protein fused with parts 
of P. falciparum MSP3 and GLURP, expressed in gram 
positive Lactococcus lactis and adjuvanted with aluminium 
hydroxide. It remains unresolved how antibodies against 
MSP3 and GLURP might exert its anti-parasitic activity, 
however recent hypothesis centred on the association of 
antibody dependent cell-mediated inhibition (ADCI) as 
well as the interaction between the antibody, parasite and 
monocytes[69,70]. Recent clinical phase II b efficacy trial of 
other asexual blood stage vaccine candidates such as apical 
membrane antigen 1 (AMA-1) and FMP-AS02A has failed 
to protect naturally exposed individuals due to the strong 
selective pressure exerted by human immune system[71,72]. 
GMZ2 is the latest series of blood stage vaccine candidates 
that are now ready to enter phase II b trial. Previous phase 
I clinical trial in both German malaria naive adults and 
malaria-exposed Gabonese individuals exhibits fine safety, 
tolerability and immunogenicity. Furthermore, GMZ2 
vaccination also induced potent antibodies and memory 
B-cells in response to both of its antigenic components. 
A multi-center phase II b studies are now underway to 
determine the feasibility and efficacy of GMZ2 targeting 
infants and children in endemic countries[67,68]. The malaria 
vaccination is progressing rapidly from the pre-clinical 
stage to clinical trials. The safety and efficacy issue, 
however, is an important consideration before its benefits 
can be realised. 
 
6. Genetic engineering
  Genetic manipulation is one of the greatest breakthroughs 
Table 2
Advantages and disadvantages of genetic engineering technologies for malaria control.
Technologies Advantages Disadvantages
Genetically modified artemisinin -  Substitute conventional A. annua leaves 
extraction[76,77]
-  Enhanced artemisinin production through 
genetically modified microbes[77]
-  Less impact to the environment[76]
-  Require multiple processes to obtain desired 
products[77]
-  Yield optimization and industrial scale-up 
are necessary[77]
Malaria vaccine - Safety and tolerability[80]
- Modifiability[79]
- Reduced risk of malaria by provide partial 
protection[56]
- Relatively weak Th1 response[80] 
- Require prime-boost regimen to increase 
efficacy[60]
Malaria proof mosquito -  Reduced lifespan and reproduction rate of 
infected mosquitoes[81]
-  Reduced transmission of P. falciparum 
malaria[81]
-  Resistance towards the anti-pathogen 
traits[83,84]
-  Occurrence of mutagenesis particularly 
mutant mosquitoes[83,84]
Transgenic fungi -  High specificity and efficacy[85]
-  Environmental friendly[85,86]
-  Wide applications[85,86]
-  Minimized development of insecticide-
resistance[85]
-  Restricted by regulatory and safety issues[90]
-  Require numerous laboratory trials and 
long-term observation[90]
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in recent research history, along with the completion of 
Human Genome Project. The advances made possible by 
genetic modification have rekindled the hope for control and 
alleviation of numerous human diseases[73]. The potential 
for genetically modified organisms (GMOs) as a control 
strategy for vector transmission diseases such as malaria 
has been sustainably driven by the selection pressure of the 
parasites and the inadequacy of current control strategies[74]. 
The implementation of recombinant DNA technologies 
in malaria control is intended to promote human health 
while investigating the cause of recurring malaria attacks 
especially in sub-Saharan Africa. Table 2 summarises 
the advantages and disadvantages of various genetically 
engineered technique designed for malaria control. 
 
7. Genetically engineered artemisinin
  Artemisinin, a lactone endoperoxide isolated from glandular 
trichomes on the leaves of Artemisia annua L. is now in high 
demand as an anti-malarial drug. But limited extracts from 
Artemisia annua have led to a supply shortage, and its high 
cost hinders the global distribution of ACTs, especially in 
Africa where malaria is endemic[75]. The yield of artemisinin 
compounds greatly depend on the quantity and age of leaves. 
Young leaves tend to have very low quantity of artemisinin 
but gradually increased while leaf developed and senesced 
suggesting that artemisinin increases and accumulates as 
the glands reach physiological maturity. The sequestration 
of artemisinin in glandular trichomes further explains why 
artemisinin is not detected in roots and side stems of the 
plant that do not bear glands[76]. With the aid of genetic 
engineering, high titres of microbially sourced artemisinic 
acid were produced through cloning with increased 
expression of an artemisinin biosynthetic gene obtained in 
Saccharomyces cerevisiae and Escherichia coli recombinants. 
The oxidation of amorpha-4,11-diene performed by 
amorphadiene synthase enzyme available from Artemisia 
annua and a novel cytochrome P450 monooxygenase play 
roles in the engineered mevalonate pathway that produce 
artemisinic acid[77,78]. As the artemisinic acid is transported 
and remains outside the transgenic microbes, the desired 
product can thus be obtained subsequent to purification and 
biotransformational processes. However, yield optimisation 
and industrial scale-up will be essential in order to fulfil 
the global requirement for artemisinin and its derivatives, as 
well as to reduce the current cost burden of ACTs[77]. 
8. Malaria-proof mosquito
  The complexity of the Plasmodium parasite lifecycle and 
the rapid reproduction of the mosquito vector greatly impact 
malaria eradication. The malaria-proof mosquito, a novel 
weapon resulting from genetic engineering to combat malaria 
infection in future, has been developed. Transmission of P. 
falciparum malaria was reduced by activating Akt signalling 
proteins in Anopheles mosquito. The Akt protein is important 
in the regulation of extensive cellular processes including 
glucose metabolism, apoptosis and antioxidant synthesis; to 
physiological mechanisms such as reproduction and insulin 
production in the mosquito mid-gut[81]. Over-expression 
of Akt in the mid-gut of Anopheles stephensi was reported 
to significantly reduce the intensity of P. falciparum by 
strengthening the mosquitoes’ innate immunity. Therefore, 
the transmission of infective sporozoites through anopheline 
mosquitoes can be eliminated[81,82]. 
  Despite the experimental success, there are two main 
hurdles obstructing the release of genetically modified 
mosquitoes for field trials. First, the malaria-proof gene 
must be given an evolutionary advantage over the natural 
population of the insects to compete with and displace them 
in the nature. Furthermore, the response of the Plasmodium 
parasite to the anti-pathogen traits varies. The Plasmodium 
parasite might negate the suppressive or killing effect of the 
anti-pathogen trait and develop resistance with its extensive 
surface antigen diversity[83].
  Second, ethical and community challenges exist to the 
release of genetically modified insects. Uncertainties 
in terms of efficacy and safety of the genetic control 
intervention might provoke widespread discussion and 
serious public mistrust. Although public perception towards 
malaria-proof mosquitoes remains open and pragmatic, 
the safety and efficacy of the transgenic arthropods need 
to be proven through multiple trials, as well as long-term 
monitoring on the impact of malaria epidemiology[84]. 
9. Transgenic fungi
  A specific, efficacious and environmentally friendly 
biopesticide employing genetically engineered fungus could 
be used to combat malaria transmission when pyrethroid-
resistant mosquitoes began to threat the effectiveness 
of current pesticide. Transgenic anti-malarial fungus is 
engineered using the entomopathogenic fungus, Metarhizium 
anisopliae (M. anisopliae). The fungal spores infect 
mosquitoes directly via cuticle attachment and colonisation, 
eventually penetrating into the haemolymph for proliferation 
while producing a mixture of organic compounds that 
cause internal damage, nutrition depletion and eventually 
mosquito death[85,86]. 
  M. anisopliae fungi have been manipulated to express 
four respective genes that could limit the transmission of 
P. falciparum in Anopheles gambiae[85]. Salivary gland and 
mid-gut peptide 1 (SM1) binds specifically to the mid-
gut epithelium and surface of the salivary glands, thereby 
inhibiting the invasion of sporozoites by competing essential 
ligands with Plasmodium[87]. The insertion of a synthetic 
[SM1]8 gene that expressed eight recurring SM1 peptides 
in M. anisopliae demonstrated a 71% sporozoite reduction 
in Plasmodium-infected mosquitoes. Subsequent to the 
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genetic manipulation, PfNPNA-1, a recombinant human 
monoclonal antibody that binds to the P. falciparum surface 
circumsporozoite protein is capable of reducing sporozoite 
counts by 85% via sporozoite agglutination. In addition, the 
insertion of antibacterial peptide scorpine, which resembles 
hybridisation between defensin and cecropin, also expressed 
90% sporozoite inhibition through its anti-plasmodial effect 
during the sporogonic stage. Co-inoculation of mosquitoes 
with spores containing the scorpine + [SM1]8: scorpine 
transformed gene showed significant sporozoite density 
reductions in salivary glands by approximately 98%[88,85].
  Notably, the toxins and transgenes expressed by the fungi 
were suggested to undermine the mosquito resistance 
mechanism, which consequently improved the efficacy of 
the pesticide towards resistant mosquitoes. The slow speed 
at which the genetically engineered fungus kills allowed 
the Anopheles mosquitoes to undergo several reproduction 
processes before death, enabling the susceptible-related 
genes to dilute the resistance gene in the next generation. 
The development of selection pressure for insecticide-
resistance can hence be minimised, and there is the 
possibility of evolution-proof transgenic fungi[86,89-94]. 
Metarhizium has wide applications in arthropods and various 
mosquito strains, and this, along with the multiple transgene 
and antimicrobial expression, further facilitates its usage in 
integrated vector management. 
  No field trial has been reported for this novel technique 
so far, but extensive laboratory testing is still in progress. 
The release of transgenic pathogens in the field is not 
only challenged by related safety issues and the tangible 
health benefits it could cause, but equally important are 
the regulatory and ethical issues. Generally, Metarhizium 
only affects its target and several closely related species; 
they are considered low risk and have shown no adverse 
effects in laboratory testing[95]. In accordance with genetic 
modification, it is less clear whether the malaria parasites 
will evolve to become 'super resistant'. Therefore, as 
with any other genetically modified organisms, the 
implementation of transgenic fungi as an anti-malaria tool 
remains uncertain. 
10. Conclusion
  Over the past few decades, the deployment of chloroquine 
and DDT were once the key tools to moving towards malaria 
eradication. However, the decline in political and financial 
support  for malaria control strategy along with the spread of 
resistant strains of the Plasmodium parasite and Anopheles 
mosquito have resulted in a resurgence of malaria globally. 
Polymorphisms of the gene encoding important proteins 
for drug binding and transport activity in Plasmodium 
spp. have been recognised as the cornerstones that induce 
anti-malarial drug resistance. Gene amplification and 
point mutations have been established as key players in 
the relationship of pfcrt and pfmdr1 genes to chloroquine 
resistance. Moreover, several field studies have suggested 
that reduced anti-folate susceptibility in P. falciparum is 
conferred by point mutations of the gene encoding DHFR 
and DHPS enzymes involved in the folate biosynthesis 
pathway. The principal mechanism for artemisinin and 
related compounds remain poorly understood; more 
important, however, is the emergence of artemisinin 
resistance, which has undermined the control of malaria. 
Assessment and identification of polymorphisms in relevant 
sequences for early detection of resistance, along with the 
translation of essential research into effective, clinically-
proven drug formulations, has rekindled the hope of 
delaying the emergence of drug-resistant parasites[96-98]. 
  Today, efforts and resources to roll back malaria are 
moving forward. Prevention is always better than a cure 
and vaccines that are capable of preventing and blocking 
the transmission of malaria infection would have a major 
impact on malaria eradication[4]. The first malaria vaccine 
RTS, S is expected be on the market by 2015; with less 
than 50% efficacy, it is clear that this new tool will have 
hard time accomplishing the ambitious goal of global 
eradication as proposed by WHO[99]. Extensive research has 
been focused on designing a rational and effective human 
vaccine against malaria. Various optimised approaches 
have undoubtedly contribute to the development of an 
optimal malaria vaccine that causes strong and long-lasting 
immune responses. Prime-boost vaccines have shown 
promise and are currently progressing through the pipeline 
of clinical testing. Other enhancement strategies such as 
genetic adjuvants and multi-valent plasmids are underway 
to amplify the efficacy of malaria vaccines in conjunction 
with renewed efforts for anti-malarial drug development[82]. 
Hence, the deployment of an efficacious malaria vaccine 
still requires some time to be realised. On the other hand, 
novel genetic control mechanisms may be employed to 
achieve eradication. Potential public resistance and ethical 
issue against these genetic control trials is the main obstacle 
towards the implementation of new interventions that could 
have impeded malaria transmission and save millions of 
lives. Open-field releases of malaria-proof mosquitoes and 
transgenic fungi will encounter multiple challenges in the 
coming years.
  Current technologies have advanced us to the identification 
of the genome of the Plasmodium parasite and Anopheles 
vector, but there is still a big gap in understanding the 
complex biology of the parasite, its correlation with 
the human immune system and its diverse antigenic 
variation[100,101]. The future of malaria control therefore relies 
on the discovery of new interventions while prolonging the 
lifespan of existing tools.
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